Literature DB >> 472712

Müllerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer.

P K Donahoe, D A Swann, A Hayashi, M D Sullivan.   

Abstract

A significant cytotoxicity index was obtained when human ovarian cancer cells in a microcytotoxicity assay were exposed during the S (DNA-synthesizing) phase of the cell cycle to purified fractions of testis exhibiting high Müllerian inhibiting substance bioactivity. The same effect was not observed when these fractions were tested against human glioblastoma or fibroblast lines. Most human ovarian cancers are said to resemble Müllerian tissues histologically. Müllerian inhibiting substance may thus deserve further study as a potential chemotherapeutic agent.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 472712     DOI： 10.1126/science.472712

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  9 in total

1.  Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.

Authors:  A E Stephen; P T Masiakos; D L Segev; J P Vacanti; P K Donahoe; D T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 2.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

3.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

Review 4.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

5.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

6.  Mullerian inhibiting substance inhibits growth of a human ovarian cancer in nude mice.

Authors:  P K Donahoe; A F Fuller; R E Scully; S R Guy; G P Budzik
Journal:  Ann Surg       Date:  1981-10       Impact factor: 12.969

Review 7.  Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors.

Authors:  Jang Heub Kim; David T MacLaughlin; Patricia K Donahoe
Journal:  Obstet Gynecol Sci       Date:  2014-09-17

8.  Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells.

Authors:  Maëva Chauvin; Véronique Garambois; Pierre-Emmanuel Colombo; Myriam Chentouf; Laurent Gros; Jean-Paul Brouillet; Bruno Robert; Marta Jarlier; Karen Dumas; Pierre Martineau; Isabelle Navarro-Teulon; David Pépin; Thierry Chardès; André Pèlegrin
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

Review 9.  Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.

Authors:  Rachael Jean Rodgers; Jason Anthony Abbott; Kirsty A Walters; William Leigh Ledger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.